BNP (B-type Natriuretic Peptide) vs PT-141 (Bremelanotide)

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

BNP (B-type Natriuretic Peptide)

BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.

Full details →

PT-141 (Bremelanotide)

PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Full details →

Side-by-Side Comparison

Aspect	BNP (B-type Natriuretic Peptide)	PT-141 (Bremelanotide)
Dose Range	25 mcg–100 mcg	1.8 mg
Frequency	1x daily	Less than daily
Cycle Length	1–4 weeks	4–12 weeks
Route	subcutaneous	subcutaneous
Mechanism	Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress.	PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system.
Typical Dosage	Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure.	FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month.
Administration	Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically.	Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols.
Side Effects	Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients.	Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur.
Best For	Recovery & Healing	Recovery & Healing